Oxycodone HCl 30mg – High-Potency Opioid for Severe Chronic Pain
(Extended-Release Formulation – Reserved for Opioid-Tolerant Patients Only)
⚠️ Critical Safety Notice
-
STRICTLY CONTRAINDICATED for opioid-naïve individuals
-
FOR USE ONLY in patients already taking ≥45mg MEDD (morphine equivalent daily dose)
-
TAMPERING RISK: Must prescribe with abuse-deterrent formulation
Therapeutic Profile
• Schedule II controlled substance (DEA)
• Duration: 12-hour controlled release
• Peak Effect: 4-6 hours post-dose
• Metabolism: Hepatic (CYP3A4/2D6)
FDA-Approved Indications
✔ Around-the-clock cancer pain management
✔ Chronic severe pain in opioid-adapted patients
✔ Palliative care when lower doses fail
Dosing Protocol
-
Minimum Tolerance Requirement:
≥45mg oral morphine equivalents/day for ≥1 week -
Conversion Guide:
30mg oxycodone ER q12h = 60mg oral morphine/day -
Administration:
Swallow whole – never crush, chew, or dissolve -
Renal Adjustment:
Reduce frequency to q24h if CrCl <30mL/min
Abuse-Deterrent Features
-
Hardened Tablet Matrix (resists crushing)
-
Viscous Gel Formation if manipulated
-
Brand Examples: OxyContin OP, Xtampza ER
Black Box Warnings
🛑 HIGH ADDICTION POTENTIAL – Abuse may lead to overdose/death
🛑 LIFE-THREATENING RESPIRATORY DEPRESSION
🛑 NEONATAL OPIOID WITHDRAWAL SYNDROME
Prescribing Requirements
• Documented Opioid Tolerance in medical record
• Pain Management Contract signed
• Naloxone Co-Prescription mandatory
• Monthly PDMP Checks required
Identification & Packaging
-
Tablet Markings:
• OxyContin OP: “OP” on one side, “30” on other
• Colors vary by manufacturer (e.g., green, gray) -
Dispensing Limits:
• 30-day supply maximum
• No automatic refills
